| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell and Tumor Biology |
1 Division of Differentiation and Carcinogenesis (A080), German Cancer Research Center, Heidelberg, Germany; 2 Institute of Biology, Romanian Academy of Science, Bucharest, Romania; and 3 ImClone Systems, Inc., New York, New York
Requests for reprints: Norbert E. Fusenig, Division of Differentiation and Carcinogenesis (A080), German Cancer Research Center, INF 280, 69120 Heidelberg, Germany. Phone: 49-6221-42-4507/4519; Fax: 49-6221-42-4551; E-mail: n.fusenig{at}dkfz.de.
Inhibition of vascular endothelial growth factor (VEGF) signaling, a key regulator of tumor angiogenesis, through blockade of VEGF receptor (VEGFR)-2 by the monoclonal antibody DC101 inhibits angiogenesis, tumor growth, and invasion. In a surface xenotransplant assay on nude mice using a high-grade malignant squamous cell carcinoma cell line (A-5RT3), we show that DC101 causes vessel regression and normalization as well as stromal maturation resulting in a reversion to a noninvasive tumor phenotype. Vessel regression is followed by down-regulation of expression of both VEGFR-2 and VEGFR-1 on endothelial cells and increased association of
-smooth muscle actinpositive cells with small vessels indicating their normalization, which was further supported by a regular ultrastructure. The phenotypic regression of an invasive carcinoma to a well-demarcated dysplastic squamous epithelium is accentuated by the establishment of a clearly structured epithelial basement membrane and the accumulation of collagen bundles in the stabilized connective tissue. This normalization of the tumor-stroma border coincided with down-regulated expression of the stromal matrix metalloproteinases 9 and 13, which supposedly resulted in attenuated turnover of extracellular matrix components permitting their structural organization. Thus, in this mouse model of a human squamous cell carcinoma cell line, blockade of VEGF signaling resulted in the reversion of the epithelial tumor phenotype through stromal normalization, further substantiating the crucial role of stromal microenvironment in regulating the tumor phenotype.
This article has been cited by other articles:
![]() |
D. Belotti, C. Calcagno, A. Garofalo, D. Caronia, E. Riccardi, R. Giavazzi, and G. Taraboletti Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion Mol. Cancer Res., April 1, 2008; 6(4): 525 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mimeault and S. K. Batra Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies Ann. Onc., October 1, 2007; 18(10): 1605 - 1619. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cheng, D.-H. Huo, D.-M. Kuang, J. Yang, L. Zheng, and S.-M. Zhuang Human Macrophages Promote the Motility and Invasiveness of Osteopontin-Knockdown Tumor Cells Cancer Res., June 1, 2007; 67(11): 5141 - 5147. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Willhauck, N. Mirancea, S. Vosseler, A. Pavesio, P. Boukamp, M. M. Mueller, N. E. Fusenig, and H.-J. Stark Reversion of tumor phenotype in surface transplants of skin SCC cells by scaffold-induced stroma modulation Carcinogenesis, March 1, 2007; 28(3): 595 - 610. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zhang, M. Jugold, E. C. Woenne, T. Lammers, B. Morgenstern, M. M. Mueller, H. Zentgraf, M. Bock, M. Eisenhut, W. Semmler, et al. Specific Targeting of Tumor Angiogenesis by RGD-Conjugated Ultrasmall Superparamagnetic Iron Oxide Particles Using a Clinical 1.5-T Magnetic Resonance Scanner Cancer Res., February 15, 2007; 67(4): 1555 - 1562. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Lederle, H.-J. Stark, M. Skobe, N. E. Fusenig, and M. M. Mueller Platelet-Derived Growth Factor-BB Controls Epithelial Tumor Phenotype by Differential Growth Factor Regulation in Stromal Cells Am. J. Pathol., November 1, 2006; 169(5): 1767 - 1783. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ansiaux, C. Baudelet, B. F. Jordan, N. Crokart, P. Martinive, J. DeWever, V. Gregoire, O. Feron, and B. Gallez Mechanism of Reoxygenation after Antiangiogenic Therapy Using SU5416 and Its Importance for Guiding Combined Antitumor Therapy Cancer Res., October 1, 2006; 66(19): 9698 - 9704. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Gutschalk, C. C. Herold-Mende, N. E. Fusenig, and M. M. Mueller Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Promote Malignant Growth of Cells from Head and Neck Squamous Cell Carcinomas In vivo Cancer Res., August 15, 2006; 66(16): 8026 - 8036. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Miller, S. Vosseler, N. Mirancea, D. J. Hicklin, P. Bohlen, H. E. Volcker, F. G. Holz, and N. E. Fusenig Rapid Vessel Regression, Protease Inhibition, and Stromal Normalization upon Short-Term Vascular Endothelial Growth Factor Receptor 2 Inhibition in Skin Carcinoma Heterotransplants Am. J. Pathol., November 1, 2005; 167(5): 1389 - 1403. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Naef and J. Huelsken Cell-type-specific transcriptomics in chimeric models using transcriptome-based masks Nucleic Acids Res., July 19, 2005; 33(13): e111 - e111. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |